Given the rapid and increasing uptake of GLP1Ra-based therapies, coupled with the knowledge gap surrounding their impact on clinically relevant bone outcomes in older adults, we conducted an exploratory post hoc analysis of a pilot trial to explore the impact of 20 weeks of semaglutide use on bone density and turnover in older adults with overweight or obesity
Authorship All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published
Clinical observations suggest that patients receiving both IV Glutathione + Vitamin C report quicker brightening than those receiving glutathione alone
Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, Akhondzadeh S, Benedetti F, Caneo C, Cramer H, Cribb L, de Manincor M, Dean O, Deslandes AC, Freeman MP, Gangadhar B, Harvey BH, Kasper S, Lake J, Lopresti A, Lu L, Metri NJ, Mischoulon D, Ng CH, Nishi D, Rahimi R, Seedat S, Sinclair J, Su KP, Zhang ZJ, Berk M
Behavioral and Mental Health Benefits GLP-1 medications may offer surprising benefits for mental health: Reduced risk of substance use disorders Decreased suicidal thoughts and self-harm behaviors Lower risk of bulimia and eating disorders Reduced risk of psychotic disorders like schizophrenia Researchers believe these benefits occur because GLP-1 receptors are found in brain areas involved in reward, addiction, and impulse control the same areas that regulate appetite
Jump to: Who should never take weight-loss injections | Conditions that need extra caution | Medications that interact | Pregnancy, breastfeeding and age | If you are scheduled for surgery | When to stop and seek help | Questions to ask your GP | Frequently asked questions | Take home message You shouldnt take weight-loss injections like Wegovy (semaglutide) or Mounjaro (tirzepatide) if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2 (MEN-2), type 1 diabetes, or have had a serious allergic reaction to a GLP-1 medication
